ESC 365 - Polymer-free amphilimus-eluting stents vs. biodegradable-polymer everolimus-eluting stents in all-comers undergoing pci: 2-year results of the PARTHENOPE trial

Open Access

Polymer-free amphilimus-eluting stents vs. biodegradable-polymer everolimus-eluting stents in all-comers undergoing pci: 2-year results of the PARTHENOPE trial

Session: Personalised PCI: special populations, innovative devices and tailored therapy

Topic: Revascularisation

Speaker: Associate Professor R. Piccolo (Naples, IT)

Event: EAPCI Summit 2026

Congress Presentation

Add to my library

About the speaker

Associate Professor Raffaele Piccolo

University of Naples Federico II, Naples (Italy)

1 presentation

0 follower

6 more presentations in this session

Cardio-kidney-metabolic phenotypes determine residual cardiovascular risk after acute coronary syndromes

Speaker: Miss Y. Wang (Zurich, CH)

Impact of cardio-oncology services on care and outcomes of STEMI patients with active cancer

Speaker: Doctor M. Dafaalla (Stoke-on-Trent, GB)

Impact of sex on residual angina after percutaneous coronary interventions

Speaker: Doctor D. Munhoz (Aalst, BE)

What makes it stentless? Development and internal validation of bailout risk score in DCB-only PCI

Speaker: Doctor L. Iossa (Mercogliano, IT)

Long-term outcomes following drug-coated balloons versus thin-strut drug-eluting stents for treatment of in-stent restenosis in acute coronary syndrome (ACS dragon-registry)

Speaker: Professor R. Januszek (Krakow, PL)

Access the full session

Personalised PCI: special populations, innovative devices and tailored therapy

Speakers: Associate Professor R. Piccolo, Miss Y. Wang, Doctor M. Dafaalla, Doctor D. Munhoz, Doctor L. Iossa...

About the event

EAPCI Summit 2026

19 February - 20 February 2026

Sessions Presentations

Congress

ESC 365 is supported by

novartis

Explore sponsored resources